Therapy results of advanced-stag Hodgkin lymphoma in Khabarovsk district


Cite item

Full Text

Abstract

Objectives. To evaluate therapy results of advanced-stag Hodgkin lymphoma (HL) in Kraev Oncology Centre, Khabarovsk district. Methods. The study included 76 patients with Hodgkin's lymphoma. They were observed in the Regional Oncology Centre in Khabarovsk district in the period from May 2007 to May 2015. The median age was 31 (range from 18 to 61 years of age). Patients received modified BEACOPP regimen therapy. Results. According to therapy results of advanced-stag HL at the median of 53 months, the median of overall survival and disease-free survival was not reached. The rates of survival were 89.1 and 94.9% respectively, and the failure free survival was 86.6%. Using of the modified BEACOPP protocol therapy was accompanied by predictable and avoidable side effects. The hematological toxicity of 3-4 degree of development of leukopenia was observed in 74.5% of cases; anemia and thrombocytopenia in 16.5 and 14.9% respectively. Conclusions. The modified BEACOPP protocol is highly effective in the treatment of Hodgkin’s lymphoma and leads to significant improvement in overall survival.

About the authors

V S Kanin

Regional Oncology Centre

Email: dr.v.kanin@gmail.com
врач-гематолог отд-ния химиотерапии ГБУЗ ККЦО 680042, Russian Federation, Khabarovsk, Voronezhskoe sh., d. 164

E S Kanin

S.I.Sergeev 1 Teaching Hospital

врач-патолог ГБУЗ КБ №1 им. проф. С.И.Сергеева 680009, Russian Federation, Khabarovsk, ul. Krasnodarskaia, d. 9

M I Dolgaleva

Regional Oncology Centre

врач-онколог отд-ния химиотерапии ГБУЗ ККЦО 680042, Russian Federation, Khabarovsk, Voronezhskoe sh., d. 164

References

  1. Пивник А.В., Шаркунов Н. Лимфома Ходжкина. Мед. совет. 2013; 5-6: 92-7.
  2. Каприн А.Д., Старинский А.Д., Петрова В.В. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). 2015: 250.
  3. Демина Е.А. Дискуссионные вопросы лечения распространенных стадий лимфомы Ходжкина. Клин. онкогематология. 2014; 7 (1): 94-5.
  4. Viviani S, Zinzani P, Rambaldi A et al. ABVD versus BEACOPP for Hodgkin's lymphoma whenhigh - dosesalvageisplanned. N Engl J Med 2011; 365 (3): 203-12. doi: 10.1056/NEJMoa1100340
  5. Carde P, Karrasch M, Fortpied C et al. Eight Cycles of ABVD Versus Four Cycles of BEACOPP escalated Plus Four Cycles of BEACOPP baseline in Stage III to IV, International Prognostic Score ≥ 3, High - Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol 2016; 34 (17): 2028-36. doi: 10.1200/JCO.2015.64.5648
  6. Wongso D, Fuchs M, Pluütschow A et al. Treatment - Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group. J Clin Oncol 2013; 31 (22): 2819-24. doi: 10.1200/JCO.2012.47.9774.
  7. Engert A, Haverkamp H, Kobe C et al. Reduced - intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage TRM in Patients With Advanced-Stage HL Treated With BEACOPP escalated Hodgkin’s lymphoma (HD15 trial): A randomised, open - label, phase 3 non - inferiority trial. Lancet 2012; 379: 1791-9. doi: 10.1016/S0140-6736(11)61940-5.
  8. Skoetz N, Trelle S, Rancea M et al. Effect of initial treatment strategy on survival of patients with advanced - stage Hodgkin's lymphoma: a systematic review and network meta - analysis Lancet 2013; 14 (10): 943-52. doi: 10.1016/S1470-2045(13)70341-3.
  9. Von Tresckow B, Moskowitz C. Treatment of relapsed and refractory Hodgkin Lymphoma. Semin Hematol. 2016; 53 (3): 180-5. doi: 10.1053/j.seminhematol.2016.05.010.
  10. Петрова Г.Д., Мелкова К.Н., Чернявская Т.З. и др. Аутологичная трансплантация гемопоэтических стволовых клеток при первично - рефрактерном течении лимфомы Ходжкина: мнимый цугцванг или промежуточный ход? Клин. онкогематология. 2015; 8 (3): 321-30.
  11. Жуков Н.В., Румянцев А.Г, Усс А.Л. Высокодозная химиотерапия с аутологичной трансплантацией гемопоэтических стволовых клеток при первичной резистентности и резистентных рецидивах лимфомы Ходжкина. Существует ли равное право на жизнь? Клин. онкогематология. 2014; 7 (3): 317-26.
  12. Chen R, Gopal A.K, Smith S.E. Five - year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 2016; 128 (12): 1562-6. doi: 10.1182/blood-2016-02-699850.
  13. Moskowitz C.H, Nademanee A, Masszi T. Brentuximab vedotin as consolidation therapy after autologous stem - cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double - blind, placebo - controlled, phase 3 trial. Lancet 2015; 385 (9980): 1853-62. doi: 10.1016/S0140-6736(15)60165-9.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies